Phase 4
Completed N=408
Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
Erosive Esophagitis
Source: ClinicalTrials.gov NCT01874535 ↗
Enrolled (actual)
408
Serious AEs
0.0%
Results posted
Sep 2018
Primary outcomePrimary: The Rates of Complete Symptom Relief — 152; 157 participants — p=<0.05
◆ Published Evidence
Established
28citations · ~3 / year
Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Summary
To investigate the impact of initial treatment duration (4-week versus 8-week)of Esomeprazole (40mg) on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
Linked Publications
-
Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Rates of Complete Symptom Relief |
152; 157 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- patients between the ages of 15 and 80 years
- with clinical symptoms of acid regurgitation, heart burn, or feeling of acidity in the stomach,
- who have Los Angeles Grade A and B erosive esophagitis proven by endoscopy are recruited.
Exclusion Criteria
- coexistence of peptic ulcer or gastrointestinal malignancies,
- pregnancy,
- coexistence of serious concomitant illness (for example, decompensated liver cirrhosis and uremia),
- previous gastric surgery,
- allergy to esomeprazole,
- symptom score of a validated questionnaire (Chinese GERDQ) less than 12, and
- equivocal endoscopic diagnosis of Los Angeles Grade A and B erosive esophagitis.
Data sourced from ClinicalTrials.gov (NCT01874535) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.